07666

6.6459.53%
HC

Hongming Chen

Co-founder, Chief Research & Development Officer and Executive Director

Dr. Hongming Chen, Sc.D., is President and Head of Research & Development at METiS Therapeutics Inc. from January 2022 and is Chief Scientific Officer, Treasurer and Secretary. She serves as the President, Chief Scientific Officer and Head of Research & Development at Be Biopharma, Inc. Dr. Chen is a Co-founder of Metis Techbio Co., LTD and has been its Executive Director since August 2025. She serves as Chief Research and Development Officer at Metis Techbio Co., LTD since December 16, 2021 and served as its Director until August 2025. Dr. Chen served as Chief Scientific Officer of Kala Pharmaceuticals, Inc., from October 2014 to December 2021. Dr. Chen joined Kala in January 2010 and is responsible for Kala's R&D activities. Dr. Chen served as Director of Formulation Development at TransForm Pharmaceuticals Inc. or TransForm, from 2000 to January 2010 and was responsible for formulation design for drugs and drug/device combinations. Prior to Kala, Dr. Hongming helped start and build TransForm Pharmaceuticals, which was acquired by Johnson & Johnson in 2005. Dr. Chen was Executive Vice President of Research at Kala Pharmaceuticals, Inc., from October 2013 to October 2014 and served as its Vice President of Research from January 2010 to October 2013. Dr. Chen was the first Employee at TransForm. Before joining TransForm, Dr. Chen conducted vaccine delivery research and development at AstraZeneca plc from 1997 to 2000 and at Merck & Co., Inc. from 1996 to 1997. In 2018, Dr. Chen was elected to the National Academy of Engineering and in 2015, Dr. Chen was elected to the College of Fellows at the American Institute for Medical and Biological Engineering. Dr. Chen received her B.S. degree in Chemical Engineering from The University of Texas at Austin in 1992 and her M.S. and Sc.D. degrees in Chemical Engineering from Massachusetts Institute of Technology in 1995 and 1997, respectively.

Positions